TrialThe American journal of psychiatry2016

Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept.

Carolyn I Rodriguez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.